VEGFA and neoplasm: Even if a treatment like bevacizumab is effective against one angiogenic factor such as VEGF, the therapy can still fail if this factor is not important for the endothelium in that given tumor, as appears to be the case in tumors that co-opt pre-existing vessels in NSCLC [45].